News

As part of the deal, both the firms will support the development and potential commercialization of at least three cancer treatments over the next decade. The agreement also

In Japan, Repatha is being developed by Amgen Astellas BioPharma, a joint venture between Amgen and Astellas Pharma, a Japanese pharmaceutical firm. Repatha inhibits proprotein convertase subtilisin/kexin type

The ongoing Phase Ib randomized, double-blind, placebo-controlled, multiple-dose PRIME trial is evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of aducanumab. The interim analysis of PRIME reflects

Currently, the company is in the final stage of study preparation for a Phase II trial in SCD with sevuparin and intends to begin patient enrollment during the

The trial showed that nearly double the percentage of patients achieved clear or almost clear skin after 12 weeks of treatment with BI 655066 compared to ustekinumab. The

In the randomized, double-blind, placebo-controlled, multi-dose trial, PBI-4050 was found to be safe and well tolerated without any serious adverse events reported. The trial’s objectives were to show

Ichorcumab is developed to mimic the activity of a human antibody which appears to produce an anticoagulated state without predisposition to bleeding. The acquisition of was identified and

In order to fund selected research projects over the course of the five year agreement, the organizations will each contribute about $2m. The deal is the result of

According to the firms, the small molecule HM71224 is ready to enter Phase II and will be examined for the potential treatment of rheumatoid arthritis, lupus, lupus nephritis,